Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...

Two asthma inhalers are being phased out, the Food and Drug Administration announced at the end of May. The Combivent Inhalation Aerosol and the Maxair Autohaler both contain chlorofluorocarbons (CFCs ...

U.S. regulators have stamped an approval on a new inhaler that reduces the required inhalations per dose for Boehringer Ingelheim's treatment for chronic obstructive pulmonary disease (COPD), the ...

Statement: “Big drug companies charge as little as $7 for an inhaler overseas and nearly $500 for the exact same one here in the US.” Are Americans paying nearly $500 for an inhaler that would cost ...

COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced a voluntary recall of over 350,000 Combivent Respimat (ipratropium ...

The U.S. Food and Drug Administration announced it will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This complies with an ...

The FDA announced that the phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) will be complete by December 31, 2013. The FDA is making an effort to comply with an ...